TAUNS Laboratories (TYO:197A) has entered into a strategic alliance with Zacros Corp. to develop and manufacture components for next-generation point-of-care testing devices, according to a Thursday filing on the Tokyo Stock Exchange.
The partnership integrates TAUNS' expertise in rapid diagnostic test kits with Zacros' biochip technology, aiming to improve diagnostic functionality and production efficiency.
The collaboration will focus on expanding applications for POCT devices and enhancing rapid test kits for infectious diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.